These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38563763)

  • 1. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    Brunet J; Choucha Z; Gransagne M; Tabbal H; Ku M-W; Buchrieser J; Fernandes P; Batalie D; Lopez J; Ma L; Dufour E; Simon E; Hardy D; Petres S; Guinet F; Strick-Marchand H; Monot M; Charneau P; Majlessi L; Duprex WP; Gerke C; Martin A; Escriou N
    J Virol; 2024 May; 98(5):e0169323. PubMed ID: 38563763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
    Lu M; Dravid P; Zhang Y; Trivedi S; Li A; Harder O; Kc M; Chaiwatpongsakorn S; Zani A; Kenney A; Zeng C; Cai C; Ye C; Liang X; Shimamura M; Liu SL; Mejias A; Ramilo O; Boyaka PN; Qiu J; Martinez-Sobrido L; Yount JS; Peeples ME; Kapoor A; Niewiesk S; Li J
    Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
    Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
    mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
    Launay O; Artaud C; Lachâtre M; Ait-Ahmed M; Klein J; Luong Nguyen LB; Durier C; Jansen B; Tomberger Y; Jolly N; Grossmann A; Tabbal H; Brunet J; Gransagne M; Choucha Z; Batalie D; Delgado A; Müllner M; Tschismarov R; Berghmans PJ; Martin A; Ramsauer K; Escriou N; Gerke C
    EBioMedicine; 2022 Jan; 75():103810. PubMed ID: 35045362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters.
    Yang ZH; Song YL; Pei J; Li SZ; Liu RL; Xiong Y; Wu J; Liu YL; Fan HF; Wu JH; Wang ZJ; Guo J; Meng SL; Chen XQ; Lu J; Shen S
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters.
    Frantz PN; Barinov A; Ruffié C; Combredet C; Najburg V; de Melo GD; Larrous F; Kergoat L; Teeravechyan S; Jongkaewwattana A; Billon-Denis E; Tournier JN; Prot M; Levillayer L; Conquet L; Montagutelli X; Tichit M; Hardy D; Fernandes P; Strick-Marchand H; Di Santo J; Simon-Lorière E; Bourhy H; Tangy F
    Nat Commun; 2021 Nov; 12(1):6277. PubMed ID: 34725327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.
    Zhang Y; Lu M; Mahesh KC; Kim E; Shamseldin MM; Ye C; Dravid P; Chamblee M; Park JG; Hall JM; Trivedi S; Chaiwatpongsakorn S; Kenny AD; Murthy SS; Sharma H; Liang X; Yount JS; Kapoor A; Martinez-Sobrido L; Dubey P; Boyaka PN; Peeples ME; Li J
    Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2201616119. PubMed ID: 35895717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine.
    Hörner C; Schürmann C; Auste A; Ebenig A; Muraleedharan S; Dinnon KH; Scholz T; Herrmann M; Schnierle BS; Baric RS; Mühlebach MD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(51):32657-32666. PubMed ID: 33257540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
    Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
    Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.
    Zhang Y; Chamblee M; Xu J; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Gupta YA; Evans JP; Lu M; Ye C; Hsu CC; Liang X; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Dubey P; Peeples ME; Li J
    Nat Commun; 2024 Jul; 15(1):5589. PubMed ID: 38961063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    Microbiol Spectr; 2024 Aug; 12(8):e0095924. PubMed ID: 38916311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Jitender ; Vikram Kumar B; Singh S; Verma G; Kumar R; Mishra PM; Kumar S; Nagaraj SK; Nag J; Joy CM; Nikam B; Singh D; Pooja ; Kalidas N; Singh S; Mumtaz ; Bhardwaj AK; Mankotia DS; Ringe RP; Gupta N; Tripathi S; Mishra RPN
    Vaccine; 2024 Aug; 42(20):126099. PubMed ID: 38981743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants.
    Metzdorf K; Jacobsen H; Kim Y; Teixeira Alves LG; Kulkarni U; Brdovčak MC; Materljan J; Eschke K; Chaudhry MZ; Hoffmann M; Bertoglio F; Ruschig M; Hust M; Šustić M; Krmpotić A; Jonjić S; Widera M; Ciesek S; Pöhlmann S; Landthaler M; Čičin-Šain L
    Front Immunol; 2024; 15():1383086. PubMed ID: 39119342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARS-CoV-2 infection.
    Zhang Y; Lu M; Thongpan I; Xu J; Kc M; Dravid P; Trivedi S; Sharma H; Liang X; Kapoor A; Peeples ME; Li J
    J Med Virol; 2023 Apr; 95(4):e28687. PubMed ID: 36941778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.
    Vanhoutte F; Liu W; Wiedmann RT; Haspeslagh L; Cao X; Boundy K; Aliprantis A; Davila M; Hartzel J; Li J; McGuire M; Ramsauer K; Tomberger Y; Tschismarov R; Brown DD; Xu W; Sachs JR; Russell K; Stoch SA; Lai E
    EBioMedicine; 2022 Jan; 75():103811. PubMed ID: 35042081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.
    Escriou N; Callendret B; Lorin V; Combredet C; Marianneau P; Février M; Tangy F
    Virology; 2014 Mar; 452-453():32-41. PubMed ID: 24606680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.